Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.

Sakamoto S, Maimaiti M, Xu M, Kamada S, Yamada Y, Kitoh H, Matsumoto H, Takeuchi N, Higuchi K, Uchida HA, Komiya A, Nagata M, Nakatsu H, Matsuyama H, Akakura K, Ichikawa T.

J Clin Med. 2019 Apr 11;8(4). pii: E489. doi: 10.3390/jcm8040489.

2.

Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy.

Yamada Y, Sakamoto S, Amiya Y, Sasaki M, Shima T, Komiya A, Suzuki N, Akakura K, Ichikawa T, Nakatsu H.

Asian J Androl. 2018 Sep-Oct;20(5):432-437. doi: 10.4103/aja.aja_24_18.

3.

Outcomes of patients older than 75 years with non-metastatic prostate cancer.

Amiya Y, Yamada Y, Sugiura M, Sasaki M, Shima T, Suzuki N, Nakatsu H, Murakami S, Shimazaki J.

Asian J Urol. 2017 Apr;4(2):102-106. doi: 10.1016/j.ajur.2016.12.001. Epub 2017 Jan 3.

4.

Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis.

Yamada Y, Sakamoto S, Shimazaki J, Sugiura M, Amiya Y, Sasaki M, Shima T, Komiya A, Suzuki N, Akakura K, Ichikawa T, Nakatsu H.

Prostate Int. 2017 Dec;5(4):143-148. doi: 10.1016/j.prnil.2017.03.001. Epub 2017 Mar 16.

5.

Treatment of locally advanced prostate cancer (Stage T3).

Amiya Y, Yamada Y, Sugiura M, Sasaki M, Shima T, Suzuki N, Nakatsu H, Murakami S, Shimazaki J.

Jpn J Clin Oncol. 2017 Mar 1;47(3):257-261. doi: 10.1093/jjco/hyw186.

PMID:
28096182
6.

Long-term outcomes of nonpalpable prostate cancer (T1c) patients treated with radical prostatectomy.

Amiya Y, Sasaki M, Shima T, Tomiyama Y, Suzuki N, Murakami S, Nakatsu H, Shimazaki J.

Prostate Int. 2015 Mar;3(1):27-30. doi: 10.1016/j.prnil.2015.02.001. Epub 2015 Feb 10.

7.

Management of men with a suspicion of prostate cancer after negative initial prostate biopsy results.

Yamamoto S, Kato M, Tomiyama Y, Amiya Y, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J.

Urol Int. 2014;92(3):258-63. doi: 10.1159/000355355. Epub 2014 Mar 12.

8.

Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.

Kamiya N, Suzuki H, Ueda T, Sato N, Nakatsu H, Mikami K, Sato N, Nomura K, Akakura K, Okano T, Ooki T, Naya Y, Ota S, Masai M, Ichikawa T.

Int J Clin Oncol. 2014 Feb;19(1):157-64. doi: 10.1007/s10147-012-0510-9. Epub 2013 Jan 9.

PMID:
23299278
9.

Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey.

Yano M, Suzuki H, Kamiya N, Kato T, Nomura K, Kuramochi H, Ohta S, Mikami K, Nakatsu H, Okano T, Onishi T, Ichikawa T.

Low Urin Tract Symptoms. 2013 Jan;5(1):5-10. doi: 10.1111/j.1757-5672.2012.00155.x. Epub 2012 May 16.

PMID:
26663241
10.

IgG4-related periureteral fibrosis presenting as a unilateral ureteral mass.

Abe H, Morikawa T, Araki A, Shima T, Nakatsu H, Fukayama M, Suzuki Y.

Pathol Res Pract. 2011 Nov 15;207(11):712-4. doi: 10.1016/j.prp.2011.08.003. Epub 2011 Sep 16.

PMID:
21925801
11.

Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.

Akaza H, Kanetake H, Tsukamoto T, Miyanaga N, Sakai H, Masumori N, Nakatsu H, Sagiyama K, Sakamoto S, Endo Y, Yamanouchi T; REDUCE Study Group.

Jpn J Clin Oncol. 2011 Mar;41(3):417-23. doi: 10.1093/jjco/hyq221. Epub 2010 Dec 1.

PMID:
21123311
12.

Case of splenogonadal fusion in an adult.

Ikeda A, Nakatsu H, Suzuki Y.

Int J Urol. 2010 Sep;17(9):826-7. doi: 10.1111/j.1442-2042.2010.02582.x. No abstract available.

13.

Outcome of patients with localized prostate cancer treated by radiotherapy after confirming the absence of lymph node invasion.

Suzuki N, Shimbo M, Amiya Y, Tomioka S, Shima T, Murakami S, Nakatsu H, Oota S, Shimazaki J.

Jpn J Clin Oncol. 2010 Jul;40(7):652-7. doi: 10.1093/jjco/hyq032. Epub 2010 Apr 8.

14.

Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.

Komiya A, Suzuki H, Awa Y, Egoshi K, Onishi T, Nakatsu H, Ohki T, Mikami K, Sato N, Araki K, Ota S, Naya Y, Ichikawa T.

Int J Urol. 2010 Jun;17(6):555-62. doi: 10.1111/j.1442-2042.2010.02518.x. Epub 2010 Apr 1.

15.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

16.

PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.

Shimbo M, Tomioka S, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J.

Jpn J Clin Oncol. 2009 Nov;39(11):727-31. doi: 10.1093/jjco/hyp091. Epub 2009 Aug 12.

PMID:
19674994
17.

[Primary carcinoid tumor of the testis metastatic to the para-aortic lymph nodes in six years after the first operation: a case report].

Sasaki M, Emura M, Kim U, Shinbo M, Shima T, Suzuki N, Tomioka S, Tanaka M, Nakatsu H, Murakami S, Suzuki Y.

Hinyokika Kiyo. 2009 Apr;55(4):233-6. Review. Japanese.

18.

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.

Homma Y, Yamaguchi O; Imidafenacin Study Group.

Int J Urol. 2009 May;16(5):499-506. doi: 10.1111/j.1442-2042.2009.02286.x. Epub 2009 Mar 29.

19.

Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.

Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, Shimbo M, Suzuki N, Nakatsu H, Ichikawa T.

Int J Urol. 2008 Jul;15(7):598-603. doi: 10.1111/j.1442-2042.2008.02058.x. Epub 2008 May 2.

20.

Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.

Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J.

Jpn J Clin Oncol. 2008 Jan;38(1):36-42. doi: 10.1093/jjco/hym153.

PMID:
18258713

Supplemental Content

Loading ...
Support Center